Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 220 publications

Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTION study): a study protocol.

Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTION study): a study protocol.

Journal: BMJ open
Published: September 26, 2025

Correction: The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study.

Correction: The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study.

Journal: Frontiers in immunology
Published: July 22, 2025

Cheminformatics-based screening and evaluation of phytochemicals as CDK2 inhibitors in colorectal cancer therapy.

Cheminformatics-based screening and evaluation of phytochemicals as CDK2 inhibitors in colorectal cancer therapy.

Journal: PloS one
Published: July 19, 2025

Comparison of the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a retrospective study.

Comparison of the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a retrospective study.

Journal: Journal of chemotherapy (Florence, Italy)
Published: July 17, 2025

From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy.

From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy.

Journal: Expert opinion on drug discovery
Published: July 11, 2025

New dosing schedules in pre-treated patients with metastatic colorectal cancer.

New dosing schedules in pre-treated patients with metastatic colorectal cancer.

Journal: Journal of gastrointestinal oncology
Published: June 23, 2025

Design, synthesis, anticancer evaluation, biological screening, and computational study of novel 6,7-dimethoxyquinazoline derivatives as VEGFR-2 inhibitors and apoptotic inducers.

Design, synthesis, anticancer evaluation, biological screening, and computational study of novel 6,7-dimethoxyquinazoline derivatives as VEGFR-2 inhibitors and apoptotic inducers.

Journal: European journal of medicinal chemistry
Published: June 14, 2025

The current landscape of quinazoline derivatives with in vivo anticancer therapeutic potential-part I.

The current landscape of quinazoline derivatives with in vivo anticancer therapeutic potential-part I.

Journal: Future medicinal chemistry
Published: June 05, 2025

Long-term survival benefit from third-line treatment for advanced colon cancer: a case report.

Long-term survival benefit from third-line treatment for advanced colon cancer: a case report.

Journal: Frontiers in immunology
Published: June 01, 2025

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial.

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial.

Journal: Frontiers in immunology
Published: May 30, 2025

Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Journal: Cancers
Published: May 24, 2025

Fruquintinib for Adult Patients With Metastatic Colorectal Cancer.

Fruquintinib for Adult Patients With Metastatic Colorectal Cancer.

Journal: American journal of therapeutics
Published: May 08, 2025
Showing 1-12 of 220

Last Updated: 10/31/2025